BFM
RARE icon

Boothbay Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Boothbay Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-108,700
Closed -$2.5M – 2405
2025
Q4 		$2.5M Buy
+108,700
New +$3.57M 0.04% 496
2025
Q3 		– Sell
-203,600
Closed -$7.4M – 2105
2025
Q2 		$7.4M Buy
203,600
+169,500
+497% +$6.11M 0.14% 189
2025
Q1 		$1.23M Buy
+34,100
New +$1.42M 0.03% 561
2020
Q3 		– Sell
-61
Closed -$477K – 1186
2020
Q2 		$477K Sell
61
-75
-55% -$4.96K 0.03% 589
2020
Q1 		$604K Buy
+136
New +$7.06K 0.05% 421

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Boothbay Fund Management's RARE Position: Q2 2026 in Review

Boothbay Fund Management increased its Ultragenyx Pharmaceutical (RARE) stake by 10% in Q2 2026, buying an estimated $363K and bringing the position to 156,612 shares worth $5.23M. The position accounts for 0.07% of the portfolio, ranked #338.

Boothbay Fund Management first reported a position in RARE in Q4 2019 and has held it in 10 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Boothbay Fund Management held 156,612 shares of Ultragenyx Pharmaceutical worth $5.23M as of Q2 2026.
  • Boothbay Fund Management bought 14,634 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $363K.
  • Ultragenyx Pharmaceutical made up 0.07% of Boothbay Fund Management's portfolio in Q2 2026, its #338 holding.
  • Boothbay Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 10 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.